These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 19119132)
1. Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors. Han H; Yu YY; Wang YH J Am Acad Dermatol; 2008 Nov; 59(5 Suppl):S80-3. PubMed ID: 19119132 [TBL] [Abstract][Full Text] [Related]
2. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors]. Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947 [TBL] [Abstract][Full Text] [Related]
3. Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome. Campbell T; Felsten L; Moore J Arch Dermatol; 2009 Nov; 145(11):1313-6. PubMed ID: 19917964 [TBL] [Abstract][Full Text] [Related]
4. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK Oncology; 2009; 76(5):326-32. PubMed ID: 19307738 [TBL] [Abstract][Full Text] [Related]
5. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor. Zheng S; Pan YL; Tao DY; Wang JL; Huang KE Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980 [TBL] [Abstract][Full Text] [Related]
6. Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones. Loughrey MB; Beshay V; Dobrovic A; Zalcberg J; Waring PM Histopathology; 2006 Jul; 49(1):99-100. PubMed ID: 16842259 [No Abstract] [Full Text] [Related]
7. [Imatinib mesylate STI571 therapy for five patients with advanced gastrointestinal stromal tumors]. Shen KT; Hou YY; Qin XY; Song LJ; Sujie A Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Mar; 8(2):129-31. PubMed ID: 16155822 [TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal stromal tumors (GISTs): a pathology view point. Sornmayura P J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254 [TBL] [Abstract][Full Text] [Related]
9. [A case of recurrent GIST successfully treated with low-dose imatinib mesilate]. Hanada N; Kawamura Y; Taneda T; Yoshida Y; Osako T; Inoue K Gan To Kagaku Ryoho; 2006 Jun; 33(6):799-801. PubMed ID: 16770100 [TBL] [Abstract][Full Text] [Related]
10. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Ménard C; Blay JY; Borg C; Michiels S; Ghiringhelli F; Robert C; Nonn C; Chaput N; Taïeb J; Delahaye NF; Flament C; Emile JF; Le Cesne A; Zitvogel L Cancer Res; 2009 Apr; 69(8):3563-9. PubMed ID: 19351841 [TBL] [Abstract][Full Text] [Related]
11. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs]. Shiba K; Matsumoto T; Hirota S Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796 [TBL] [Abstract][Full Text] [Related]
12. Kit as a human oncogenic tyrosine kinase. Kitamura Y; Hirotab S Cell Mol Life Sci; 2004 Dec; 61(23):2924-31. PubMed ID: 15583854 [TBL] [Abstract][Full Text] [Related]
13. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience. Wong DW; Lupton SC; Bhatt L; Gross L; Tanière P; Peake DR; Spooner D; Geh JI Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):517-22. PubMed ID: 18514495 [TBL] [Abstract][Full Text] [Related]
14. Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate. Ferraresi V; Catricalà C; Ciccarese M; Ferrari A; Zeuli M; Cognetti F Anticancer Res; 2006; 26(6C):4771-4. PubMed ID: 17214339 [TBL] [Abstract][Full Text] [Related]
15. Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour. Grabellus F; Ebeling P; Worm K; Sheu SY; Antoch G; Frilling A; Schmid KW Gut; 2007 Jul; 56(7):1025-6. PubMed ID: 17566038 [No Abstract] [Full Text] [Related]
16. KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors. De Giorgi U J Clin Oncol; 2007 Mar; 25(9):1146-7; author reply 1147-8. PubMed ID: 17369583 [No Abstract] [Full Text] [Related]
17. Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate. Boruban C; Sencan O; Akmansu M; Atik ET; Ozbek S Anticancer Drugs; 2007 Sep; 18(8):969-72. PubMed ID: 17667604 [TBL] [Abstract][Full Text] [Related]